Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 1
1958 1
1964 1
1969 4
1970 5
1972 8
1973 7
1974 7
1975 3
1976 3
1977 2
1978 2
1979 5
1980 5
1981 1
1982 3
1983 8
1984 6
1985 4
1986 3
1987 5
1988 3
1989 4
1990 6
1991 7
1992 4
1993 10
1994 8
1995 5
1996 7
1997 4
1998 3
1999 8
2000 8
2001 5
2002 2
2003 7
2004 5
2005 6
2006 7
2007 5
2008 13
2009 11
2010 18
2011 8
2012 10
2013 11
2014 11
2015 19
2016 22
2017 15
2018 21
2019 27
2020 24
2021 32
2022 23
Text availability
Article attribute
Article type
Publication date

Search Results

436 results
Results by year
Filters applied: . Clear all
Page 1
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. Among authors: jamieson c. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Shalapour S, et al. Among authors: jamieson c. Nature. 2015 May 7;521(7550):94-8. doi: 10.1038/nature14395. Epub 2015 Apr 29. Nature. 2015. PMID: 25924065 Free PMC article.
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Zhou Y, et al. Among authors: jamieson c. Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):e2025840118. doi: 10.1073/pnas.2025840118. Proc Natl Acad Sci U S A. 2021. PMID: 33602823 Free PMC article.
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand.
Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Schultz PG, Kim CH, Young TS. Lee SC, et al. Among authors: jamieson cam. Sci Adv. 2021 Aug 11;7(33):eabi8193. doi: 10.1126/sciadv.abi8193. Print 2021 Aug. Sci Adv. 2021. PMID: 34380625 Free PMC article.
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S, Floden L, Blackowicz M, Jamieson C, Popova V, Fedgchin M, Drevets WC, Cooper K, Lane R, Singh J. Hudgens S, et al. Among authors: jamieson c. J Affect Disord. 2021 Feb 15;281:767-775. doi: 10.1016/j.jad.2020.11.066. Epub 2020 Nov 14. J Affect Disord. 2021. PMID: 33261932 Free article. Clinical Trial.
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Choi MY, et al. Among authors: jamieson c. Cell Stem Cell. 2018 Jun 1;22(6):951-959.e3. doi: 10.1016/j.stem.2018.05.018. Cell Stem Cell. 2018. PMID: 29859176 Free PMC article. Clinical Trial.
436 results